Sector Expert: Francois Brisebois

Laidlaw & Company

Subscribe to
Streetwise Reports

Companies Commented On

Recent Interviews

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story' (6/29/17)
beakers blacknblue630.jpg

Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs.

Recent Quotes

"We donít believe DRRX could have asked for a better partner as Sandoz has a team of dedicated institutional sales professionals with significant presence in the hospital market."

— Francois Brisebois, Laidlaw & Company (5/11/17)

"We see the deal with DRRX and Sandoz AG as relatively heavily front loaded and are encouraged by this large pharma validation."

— Francois Brisebois, Laidlaw & Company (5/8/17)

Due to permission requirements, not all quotes are shown.